Total Results: 7179
The Vermont senator and former presidential candidate is championing the measure to curb high drug prices, which recent polls suggest is supported by more than half of Californians.
Surprise medical bill protections for consumers and new painkiller prescribing requirements for doctors are among measures signed by Gov. Jerry Brown.
Commentators analyze how the election could affect health care and policy in California.
One solution to the EpiPen controversy, some advocates say, is classifying it as preventive care so consumers wouldn’t have to pay anything for the life-saving drug. But while the suggestions seems to favor consumers, a New York Times report finds Mylan is pulling the strings.
The influx of retail chains is part of a community-based health care movement, but the trend worries some merchants and residents.
The problem, known as balance billing, happens when patients are treated by an out-of-network professional at an in-network facility. Gov. Jerry Brown is expected to sign the legislation. In other news from Sacramento, regulators could learn lessons from Colorado if recreational marijuana use becomes legal in California.
Chief Executive Heather Bresch will testify in front of the House Oversight and Government Reform Committee next week. Meanwhile, senators will introduce a bill requiring drugmakers to give a 30-day notice and justification of any prescription drug price increase of more than 10 percent. And The Associated Press examines pharmaceutical discount cards.
The Kaiser Family Foundation analysis finds that premiums for health insurance family plans offered through a workplace grew about 3 percent. Yet that was partly the result of employers shifting costs to workers through increased deductibles, which have grown nearly six times as fast as wages.
The top five managers took home almost $300 million over the past five years, The Wall Street Journal reports amid continuing questions about the manufacter’s EpiPen pricing. News outlets also report on an FDA warning to doctors about drug risks, the pros and cons of pharmaceutical ads and a drop in the cost of generics.
If the bill is signed, patients who go to a covered facility would only be charged in-network fees, no matter who treats them.